{
  "id": "coenzyme-q",
  "title": "Coenzyme Q",
  "lang": "en",
  "source_lang": "en",
  "summary": "Coenzyme Q is a membrane-soluble electron carrier essential to respiration, with additional roles in antioxidant defense and cellular metabolism.",
  "category": "science",
  "subcategory": "biology",
  "type": "concept",
  "aliases": [
    "Ubiquinone",
    "CoQ",
    "Ubiquinone-n"
  ],
  "generated_at": "2026-11-02",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/coenzyme-q/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/coenzyme-q/",
      "json": "https://aiwiki.page/zh/coenzyme-q.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Coenzyme Q is a family of lipid-soluble quinones that transfer electrons within biological membranes. In humans, the predominant member is coenzyme Q10, whose side chain contains ten isoprene units. Its best-established function is in the inner membrane of the mitochondrion, where it connects several electron-donating enzymes to the respiratory chain. This electron transfer supports the production of adenosine triphosphate (ATP), the principal chemical energy currency of cells.\n\nThe name ubiquinone refers to the widespread occurrence of the oxidized compound; its fully reduced form is ubiquinol. These forms participate in a reversible chemical cycle rather than functioning as separate nutrients. In addition to respiration, coenzyme Q contributes to membrane antioxidant defenses and links mitochondrial activity to several other metabolic pathways. Its endogenous synthesis, inherited deficiencies, and use in dietary supplements have made it an important subject in biochemistry, mitochondrial medicine, and clinical research."
    },
    {
      "heading": "Molecular structure and redox chemistry",
      "text": "Coenzyme Q consists of a substituted 1,4-benzoquinone ring attached to a long polyisoprenoid side chain. The ring carries two methoxy groups and a methyl group; the side chain contains a species-dependent number of five-carbon isoprene units. In the notation CoQ\\(_n\\), the subscript identifies the number of these units, not the number of quinone rings. Human CoQ10 has the molecular formula \\(\\mathrm{C}_{59}\\mathrm{H}_{90}\\mathrm{O}_{4}\\) and a molar mass of approximately \\(863.34\\ \\mathrm{g\\,mol^{-1}}\\). Its naturally occurring side chain has predominantly trans double-bond geometry.\n\nThe two structural regions have different functions. The quinone head undergoes oxidation–reduction reactions, while the hydrocarbon-rich tail keeps the molecule associated with lipid membranes. Coenzyme Q is therefore poorly soluble in water and does not circulate through the aqueous interior of cells as a freely dissolved carrier. Its hydrophobicity also affects extraction procedures, pharmaceutical formulation, and intestinal absorption. The side chain anchors the molecule, but the polar head must still enter and leave binding pockets in membrane-associated enzymes.\n\nThree redox states are biologically important: oxidized ubiquinone, the one-electron-reduced semiquinone, and fully reduced ubiquinol. The overall two-electron reaction can be written as\n\n\\[\\mathrm{Q}+2e^-+2\\mathrm{H}^+ \\rightleftharpoons \\mathrm{QH}_2.\\]\n\nThe semiquinone intermediate permits coenzyme Q to connect pathways involving two-electron transfers with proteins that transfer one electron at a time. Depending on the local environment and protonation state, semiquinone can occur as a neutral radical or a radical anion. Protein binding strongly affects its stability and reactivity. Semiquinone stabilized in an enzyme active site is consequently not equivalent to a freely exposed radical in a membrane.\n\nThe redox behavior of coenzyme Q depends on pH, membrane composition, protein interactions, and the relative abundance of oxidized and reduced molecules. Its midpoint potential is thus not a single context-independent property. Under suitable conditions, semiquinone can transfer an electron to oxygen, producing superoxide; in other circumstances, reduced coenzyme Q suppresses oxidative chain reactions. This duality reflects the chemistry of a reversible electron carrier, rather than a contradiction between “antioxidant” and “pro-oxidant” identities. The direction and consequences of electron transfer depend on the surrounding reaction network."
    },
    {
      "heading": "Electron transport and the Q cycle",
      "text": "In mitochondrial cellular respiration, coenzyme Q is a mobile component of the electron transport chain. Complex I, or NADH:ubiquinone oxidoreductase, transfers electrons from NADH to ubiquinone. Complex II, or succinate dehydrogenase, supplies electrons during the oxidation of succinate to fumarate in the citric acid cycle. Both pathways produce ubiquinol, but only complex I directly couples its reaction to proton pumping across the inner mitochondrial membrane.\n\nUbiquinol subsequently transfers electrons to complex III, the cytochrome \\(bc_1\\) complex. Complex III passes them to cytochrome c, a small protein on the outer face of the inner membrane, and cytochrome c delivers them to complex IV. Complex IV reduces oxygen to water. Coenzyme Q therefore occupies a central collecting point: electrons from different substrates converge on the Q pool before moving toward the terminal oxygen-reducing machinery.\n\nComplex III uses the Q cycle to couple electron transfer to proton translocation. At its \\(Q_o\\) site, located toward the intermembrane-space side, ubiquinol releases two protons and transfers its electrons into separate branches. One electron passes through the Rieske iron–sulfur protein and cytochrome \\(c_1\\) to cytochrome c. The other travels through the two b-type hemes toward a quinone at the matrix-facing \\(Q_i\\) site. Two turnovers at the \\(Q_o\\) site allow reduction of this quinone to ubiquinol, with uptake of two protons from the matrix.\n\nThe net reaction for the complete cycle can be represented as\n\n\\[\\mathrm{QH}_2+2\\,\\mathrm{cyt\\,c}_{\\mathrm{ox}} +2\\mathrm{H}^{+}_{\\mathrm{matrix}} \\rightarrow \\mathrm{Q}+2\\,\\mathrm{cyt\\,c}_{\\mathrm{red}} +4\\mathrm{H}^{+}_{\\mathrm{intermembrane}}.\\]\n\nThis chemistry helps establish the electrochemical gradient used by ATP synthase during oxidative phosphorylation. Coenzyme Q does not synthesize ATP directly; it enables electron flow and proton separation that make ATP synthesis energetically favorable.\n\nThe Q pool is also a regulatory junction. When it becomes highly reduced and the proton-motive force is sufficiently large, electrons can move backward through complex I in reverse electron transport. This process can generate substantial amounts of reactive oxygen species under particular experimental and physiological conditions. Although respiratory complexes form larger assemblies called supercomplexes, the degree to which these structures restrict coenzyme Q exchange remains an active research question. Structural proximity does not by itself establish that each assembly contains a completely isolated Q pool."
    },
    {
      "heading": "Biosynthesis and intracellular organization",
      "text": "Humans synthesize coenzyme Q rather than depending exclusively on dietary intake. Its production requires the construction of both the aromatic head-group precursor and the polyisoprenoid tail, their attachment, and a sequence of chemical modifications. The pathway involves proteins encoded in the nuclear genome, many of which act at the inner mitochondrial membrane. Because the final molecule is highly hydrophobic, its synthesis also requires mechanisms that organize membrane-associated intermediates and enzymes.\n\nThe side chain is derived from the mevalonate pathway, which also supplies precursors for cholesterol and several other isoprenoid products. In humans, the PDSS1–PDSS2 enzyme complex makes the ten-unit prenyl diphosphate used for CoQ10. COQ2 then transfers this chain to 4-hydroxybenzoate, an aromatic precursor derived from amino-acid metabolism. Subsequent reactions modify the ring through hydroxylation, methylation, and decarboxylation steps. The exact sequence and organization of these reactions have been clarified through studies of yeast, cultured mammalian cells, and inherited human disorders.\n\nSeveral named COQ proteins have direct catalytic roles. COQ3 and COQ5 are methyltransferases, while COQ6 and COQ7 participate in hydroxylation reactions. Other proteins support the stability, organization, or regulation of the biosynthetic machinery. COQ4, for example, is important for the integrity of the pathway, and the atypical kinase-family proteins COQ8A and COQ8B support coenzyme Q biosynthesis. Their function is more complex than that of a conventional protein kinase acting on a simple soluble substrate.\n\nThese components form a functional assembly often termed the CoQ synthome or complex Q. In yeast, biosynthetic proteins and intermediates can concentrate in specialized mitochondrial membrane domains. Disruption of one component may destabilize others, so a defect in a single gene can reduce the output of the whole pathway. Consequently, the biochemical consequences of a pathogenic variant cannot always be inferred solely from the isolated reaction normally associated with its protein.\n\nSynthesis and distribution are distinct problems. Coenzyme Q must reach different mitochondrial regions and nonmitochondrial membranes, yet its poor aqueous solubility prevents unrestricted diffusion through the cytosol. Lipid-binding proteins, membrane contacts, and intracellular trafficking systems participate in its movement. Members of the STARD7 protein family have been implicated in coenzyme Q distribution in mammalian cells. How production is coordinated with delivery to the plasma membrane and other destinations remains less completely understood than the core respiratory reactions."
    },
    {
      "heading": "Occurrence, homologues, and evolutionary relationships",
      "text": "The number of isoprene units in coenzyme Q varies among organisms. CoQ10 predominates in humans and many other mammals, whereas CoQ9 is the major form in mice and rats. The budding yeast Saccharomyces cerevisiae principally produces CoQ6, and Escherichia coli commonly produces CoQ8. These patterns are useful biochemical characteristics, although organisms can contain mixtures of homologues rather than a single chemically uniform form. Side-chain length largely reflects the specificity of the enzymes that synthesize the prenyl precursor.\n\nCoenzyme Q is widespread among eukaryotes and many bacteria, but it is not the universal electron carrier of every membrane-based energy system. Many bacteria use menaquinone, a vitamin K-related naphthoquinone, either instead of ubiquinone or alongside it. Quinone composition can change with growth conditions, especially oxygen availability. Differences in redox potential and enzyme compatibility help explain why different quinones serve different respiratory pathways.\n\nIn oxygenic photosynthesis, the analogous mobile carrier is plastoquinone. It moves electrons between photosystem II and the cytochrome \\(b_6f\\) complex in thylakoid membranes. Plastoquinone resembles ubiquinone in having a redox-active head and a hydrophobic isoprenoid tail, but its ring substitution and biological partners differ. The two compounds illustrate a common solution to membrane electron transfer without being interchangeable components of the same pathway.\n\nMitochondrial coenzyme Q metabolism is also connected to endosymbiotic theory. Mitochondria descend from a bacterial lineage, and their respiratory membranes retain biochemical features of bacterial energy metabolism. Over evolutionary time, most genes involved in mitochondrial function moved to, or became coordinated with, the nuclear genome. Present-day coenzyme Q biosynthesis therefore combines an organelle-associated biochemical pathway with predominantly nuclear genetic control.\n\nWithin animals, coenzyme Q is present in numerous tissues, with amounts and redox states differing according to tissue composition and metabolic activity. It is also found outside mitochondria, including in the plasma membrane and circulating lipoproteins. This wider distribution explains why its biology cannot be reduced to mitochondrial ATP production alone. At the same time, measurements from one compartment cannot automatically describe another: circulating CoQ10 is strongly influenced by lipoprotein concentrations, whereas tissue coenzyme Q depends on local synthesis, transport, turnover, and cellular composition. Comparisons across species must additionally account for differences in the predominant homologue."
    },
    {
      "heading": "Antioxidant defenses and other metabolic functions",
      "text": "Ubiquinol can interrupt lipid oxidation by donating reducing equivalents to lipid-derived radicals. This activity matters because membrane lipids can undergo self-propagating oxidation reactions that damage their structure and generate reactive breakdown products. Coenzyme Q participates in a broader antioxidant network rather than acting in isolation. In suitable chemical environments, ubiquinol can help regenerate the reduced form of vitamin E, whose tocopherol molecules also interrupt lipid-radical chain reactions.\n\nA major nonmitochondrial pathway involves ferroptosis suppressor protein 1, usually abbreviated FSP1 and formerly called AIFM2. Studies published in 2019 established that this enzyme reduces coenzyme Q using cellular reducing equivalents and thereby protects membranes against ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation. Membrane association is important to FSP1 function. The FSP1–CoQ system operates alongside, but separately from, the glutathione-dependent enzyme GPX4, another major defense against lipid peroxide accumulation.\n\nThese findings distinguish the existence of an endogenous protective mechanism from claims about oral supplementation. Demonstrating that cells require reduced coenzyme Q for antioxidant defense does not establish that additional ingested CoQ10 reaches a particular membrane, increases its reduced pool, or changes a clinical outcome. The local balance between reduction, oxidation, transport, and synthesis determines the effectiveness of the system.\n\nCoenzyme Q also accepts electrons from several mitochondrial enzymes beyond complexes I and II. Electron-transferring flavoprotein:ubiquinone oxidoreductase connects the Q pool to fatty-acid oxidation and the breakdown of certain amino acids. Mitochondrial glycerol-3-phosphate dehydrogenase transfers reducing equivalents from the glycerol phosphate shuttle to ubiquinone. Sulfide:quinone oxidoreductase supplies another connection, coupling sulfide oxidation to quinone reduction. Thus, the Q pool integrates chemically diverse substrates into a common respiratory route.\n\nAn especially important relationship involves dihydroorotate dehydrogenase, or DHODH. In mammalian cells, this inner-membrane enzyme oxidizes dihydroorotate to orotate during de novo pyrimidine synthesis and transfers electrons to ubiquinone. Pyrimidines are required to make nucleotides, including building blocks of DNA and RNA. Respiratory-chain activity can therefore influence biosynthesis as well as ATP production by determining whether sufficient oxidized ubiquinone is available for DHODH. Mitochondrial DHODH activity has also been linked experimentally to protection against lipid peroxidation, further connecting intermediary metabolism with membrane redox defense."
    },
    {
      "heading": "Inherited deficiency and disease mechanisms",
      "text": "Primary coenzyme Q deficiency comprises rare inherited disorders caused by defects in the biosynthetic pathway. Established disease-associated genes include PDSS1, PDSS2, COQ2, COQ4, COQ6, COQ7, COQ8A, COQ8B, and COQ9. Many of these conditions follow autosomal recessive inheritance, in which disease results from pathogenic variants affecting both copies of the relevant gene. They are genetically and clinically heterogeneous rather than a single uniform syndrome.\n\nThe consequences follow from coenzyme Q’s position at the intersection of respiration and other metabolic functions. A depleted Q pool can impair electron transfer from multiple substrates, reduce oxidative ATP production, and disturb redox balance. The severity depends on residual biosynthetic activity, the distribution of the affected protein, and tissue-specific metabolic requirements. Organs with substantial energy demands, including the brain, skeletal muscle, heart, and kidneys, can be involved, but the precise pattern differs markedly among genetic forms.\n\nRecognized presentations include early-onset multisystem disease, encephalopathy, myopathy, cerebellar ataxia, and kidney disease. COQ8A-related disease is notably associated with cerebellar ataxia. Pathogenic variants in COQ8B are an established cause of steroid-resistant nephrotic syndrome, and COQ6 disease can combine nephrotic syndrome with sensorineural hearing impairment. These associations are useful for classification, but they are not absolute rules: variants in the same gene can produce different ages of onset and degrees of organ involvement.\n\nSecondary reductions in coenzyme Q occur in some disorders not caused directly by defects in COQ-pathway genes. This distinction matters because a low tissue measurement is a biochemical finding, not by itself a complete genetic diagnosis. It must be interpreted together with clinical features, respiratory-chain studies, and molecular findings. A concentration measured in blood does not reliably establish whether the brain, kidney, or skeletal muscle has a deficient intracellular pool.\n\nOral coenzyme Q has been used in primary deficiency, with responses documented in some patients, particularly for certain renal manifestations. However, response varies with genotype, organ involvement, disease duration, and the extent of established injury. Neurological disease may be less responsive, in part because delivery to the central nervous system is limited and irreversible tissue damage may already be present. Much of the evidence comes from case reports and observational series, reflecting the rarity of these disorders. The existence of responsive inherited deficiencies does not establish effectiveness for unrelated diseases in people with normal coenzyme Q synthesis."
    },
    {
      "heading": "Measurement and experimental investigation",
      "text": "Coenzyme Q can be measured in plasma, cultured cells, or tissue extracts. A central analytical distinction is between total coenzyme Q and its redox state. Total CoQ10 includes oxidized ubiquinone-10 and reduced ubiquinol-10, whereas the reduced fraction describes the proportion present as ubiquinol. These measurements answer different questions. Total concentration concerns pool size; the redox ratio reflects oxidation and reduction within that pool, while remaining highly sensitive to collection and handling.\n\nMost assays begin with organic-solvent extraction because coenzyme Q is strongly lipid-soluble. High-performance liquid chromatography separates coenzyme Q from other lipids and can distinguish homologues or redox forms. Detection may use ultraviolet absorbance, electrochemical methods, or mass spectrometry. Liquid chromatography–tandem mass spectrometry offers high analytical specificity and can incorporate isotope-labeled internal standards to correct for extraction losses and matrix effects. Chromatographic methods are also used to measure biosynthetic intermediates.\n\nSample preservation is especially important when determining ubiquinol. Exposure to air, light, inappropriate temperatures, or prolonged processing can oxidize it after collection, creating an apparent biological change that actually occurred in the tube. Valid redox measurements therefore depend on procedures designed to minimize ex vivo oxidation. Laboratories must also establish whether reported values refer to oxidized CoQ10 alone, total CoQ10 after chemical conversion, or separately measured redox forms.\n\nPlasma results require particular care in interpretation because much of circulating coenzyme Q is carried by lipoproteins. A change in cholesterol or lipoprotein concentration can alter plasma CoQ10 without a corresponding change in tissue mitochondrial content. For this reason, studies sometimes report CoQ10 relative to cholesterol as well as per unit plasma volume. Tissue measurements likewise depend on the denominator used: values per wet weight, total protein, or a mitochondrial marker are not directly equivalent.\n\nFunctional assays provide complementary evidence. In isolated mitochondria or tissue homogenates, combined complex I–III and complex II–III activities depend on endogenous coenzyme Q-mediated electron transfer. Reduced activity may support a Q-related defect, but it can also result from abnormalities elsewhere in the respiratory system. Genetic analysis, precursor measurements, and experiments testing whether added quinone restores activity can help distinguish possibilities. Cultured fibroblasts, yeast mutants, and engineered cell lines are widely used to investigate COQ proteins, although a result in cultured skin cells does not necessarily reproduce the metabolic state of an affected kidney or nervous system."
    },
    {
      "heading": "Dietary intake, formulations, and clinical evidence",
      "text": "CoQ10 is present in foods, including meat, fish, and some nuts and oils, but endogenous synthesis is a major source in humans. It is not conventionally classified as an essential vitamin because healthy human cells can make it. Supplement products usually contain either oxidized ubiquinone or reduced ubiquinol. Their labels therefore refer to different starting redox forms of the same interconvertible coenzyme, not to entirely separate biological pathways.\n\nOral absorption is limited by poor water solubility and is influenced by crystal dispersion, lipid vehicles, food intake, and formulation. Oil-based preparations, emulsions, and other delivery systems have been developed to improve exposure. Following absorption, coenzyme Q is transported in lipoproteins, and much of the circulating pool is reduced. Studies comparing products do not support assuming that redox form alone determines bioavailability: manufacturing and formulation can materially affect the result. An increase in plasma concentration also does not establish delivery to every target tissue.\n\nClinical research has examined CoQ10 in heart failure, neurological disorders, migraine, and statin-associated muscle symptoms, among other conditions. In the Q-SYMBIO trial, published in 2014, 420 patients with chronic heart failure were randomized to adjunctive CoQ10 or placebo; the investigators reported fewer major adverse cardiovascular events over two years in the CoQ10 group. Reviews of this field nevertheless evaluate the limitations of trial size, differences between studies, and applicability alongside other treatments. A positive result in one population is not evidence for a general cardiovascular benefit in all users.\n\nLarger neurological trials have provided important negative findings. A phase III trial published in 2014 did not show that high-dose CoQ10 slowed progression in early Parkinson disease. The 2CARE study in Huntington disease was stopped for futility. These results show why biochemical plausibility and favorable findings in model systems cannot substitute for disease-specific randomized controlled trials. For statin-associated muscle symptoms, trial results and reviews have been inconsistent. Although statins can lower circulating CoQ10, they also lower the lipoproteins that carry it, complicating interpretation of plasma measurements.\n\nReported adverse effects of oral preparations are generally gastrointestinal, but tolerability does not establish efficacy, and potential drug interactions remain relevant. Interactions affecting warfarin anticoagulation have been reported. Regulatory classification also differs among countries: a product marketed as a dietary supplement is not thereby an approved treatment for the diseases investigated in research. Clinical interpretation therefore depends on the particular disorder, population, preparation, outcome, and quality of evidence rather than on coenzyme Q’s general importance in cellular physiology."
    },
    {
      "heading": "Discovery and development of research",
      "text": "Coenzyme Q was isolated in 1957 by Frederick L. Crane and colleagues working in David E. Green’s laboratory at the University of Wisconsin–Madison. They obtained a quinone from beef-heart mitochondria and established its association with electron transport. Its discovery emerged from efforts to identify the individual components of the respiratory chain, at a time when the biochemical organization of mitochondrial energy conversion was still being resolved.\n\nIn 1958, work associated with Karl Folkers and collaborators established the chemical structure of coenzyme Q10. The name ubiquinone, introduced through work by R. A. Morton’s group, reflected the compound’s broad biological distribution. The designations “coenzyme Q” and “ubiquinone” subsequently became closely associated, although they emphasize different aspects: the former its biochemical function and the latter the oxidized quinone structure. Identification of homologues with different side-chain lengths established that the discovery concerned a molecular family rather than a single universally identical compound.\n\nUnderstanding its energetic role depended on developments beyond the molecule itself. Peter Mitchell’s chemiosmotic theory, introduced in 1961, explained how electron transfer could support ATP synthesis through a transmembrane proton gradient. His Q-cycle model, developed in the 1970s, provided a mechanistic account of how quinone chemistry at complex III could contribute to that gradient. These ideas connected a mobile lipid-soluble carrier with the physical organization of membrane bioenergetics.\n\nLater research expanded in several directions. Biochemical genetics in yeast identified many COQ genes and provided systems for testing their functions. The recognition of human primary coenzyme Q deficiency connected these pathways to inherited neurological, muscular, and renal disease. Improved chromatography and mass spectrometry made it possible to quantify small pools, distinguish homologues, and investigate pathway intermediates with increasing precision.\n\nStructural methods, including X-ray crystallography and cryo-electron microscopy, have revealed quinone-binding sites and the architecture of respiratory complexes. Meanwhile, the identification of FSP1-dependent coenzyme Q reduction in 2019 established a major connection to ferroptosis control outside the classical respiratory chain. Current investigations include the organization of biosynthetic membrane domains, exchange between mitochondrial and nonmitochondrial pools, and the mechanisms that maintain reduced coenzyme Q in specific cellular locations. Each problem requires distinguishing the total amount of the molecule from its accessibility, redox state, and local enzymatic partners."
    }
  ],
  "links": [
    "mitochondrion",
    "adenosine-triphosphate",
    "biochemistry",
    "redox-reaction",
    "water",
    "enzyme",
    "electron",
    "ph",
    "oxygen",
    "cellular-respiration",
    "electron-transport-chain",
    "citric-acid-cycle",
    "electrochemical-gradient",
    "atp-synthase",
    "oxidative-phosphorylation",
    "genome",
    "mevalonate-pathway",
    "cholesterol",
    "gene",
    "eukaryote",
    "bacteria",
    "photosynthesis",
    "thylakoid",
    "endosymbiotic-theory",
    "amino-acid",
    "nucleotide",
    "diagnosis",
    "chromatography",
    "mass-spectrometry",
    "randomized-controlled-trial",
    "x-ray-crystallography",
    "cryo-electron-microscopy"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}